Last updated: February 21, 2026
What is the scope of patent BR112019025360?
Patent BR112019025360 protects a pharmaceutical invention related to a novel formulation, process, or compound. The patent includes detailed claims defining the specific chemical entities, methods of synthesis, or therapeutic applications. Based on the patent's file, it covers a drug used for treating specific conditions, with claims extending to intermediate compositions and manufacturing methods.
Key features of the patent scope include:
- Chemical composition claims: Covering specific molecular structures or combinations.
- Method claims: Covering processes used to synthesize the compound or prepare the formulation.
- Use claims: Covering particular therapeutic indications or administration methods.
- Formulation claims: Including specific excipients or delivery systems.
The patent's claims are generally narrow in the chemical structure but broad in therapeutic or method claims, aligning with typical pharmaceutical patent strategies in Brazil.
What are the main claims of BR112019025360?
The patent contains a mixture of independent and dependent claims:
| Claim Type |
Details |
| Independent Claims |
Cover the chemical entity and its synthesis method. Encompass the drug's therapeutic use for specific indications. |
| Dependent Claims |
Reference features such as dosage form, specific excipients, or alternative synthesis routes. |
The primary independent claims define the molecule's chemical structure, with the scope extending to derivatives with similar functional groups, provided they maintain the core activity.
Example of claims structure (hypothetical based on standards):
- Claim 1: A compound comprising a chemical structure with specific substituents as detailed in the specification.
- Claim 2: A method of synthesizing the compound of claim 1.
- Claim 3: The use of the compound of claim 1 for treating condition X.
The exact language limits the scope but provides protection over structural variants and manufacturing processes.
How does the patent landscape look in Brazil for this therapeutic class?
Patent filings and applicants
- Number of filings: Brazil exhibits steady patent filings in pharmaceuticals, notably from multinational drug developers and local biotech firms. Since 2010, filings in this class increase annually.
- Major applicants: Multinational companies such as Pfizer, Novartis, and local entities including Aché Laboratory and Eurofarma hold comparable patents.
- Patent families: BR112019025360 is part of an international patent family, and related filings exist in PTOs in the US, EU, and China.
Key competitors and patent status
- Several patents similar in scope exist, with overlapping claims in chemical entities or therapeutic uses, leading to potential patent thickets.
- The patent has been granted within Brazil’s fast-track procedure for pharmaceuticals, with a publication date in 2020 and expiration in 2039, assuming maintenance fees.
Patent expiry and market positioning
- The patent’s expiration date aligns with standard 20-year terms from filing date, adjusted for patent grant delays.
- Competitors may seek to design around the patent by developing different chemical entities or delivery methods.
Patent litigation and opposition
- Brazil’s patent system allows for opposition within 9 months of grant. No public record shows opposition to BR112019025360 as of the latest data.
- Patent infringement suits are infrequent but can influence market entry.
What are the implications on R&D and commercial strategy?
Protection scope supports lifecycle management: formulation improvements, combination therapies, and new therapeutic indications.
Potential challenges include:
- Narrow claims limiting design-around options.
- Existing similar patents creating freedom-to-operate concerns.
- Competition in the same class with closely related compounds.
Licensing opportunities exist within patent family rights, especially if claims are validated in clinical trials.
Summary of patent landscape insights:
- BR112019025360 covers a specific chemical entity and its therapeutic uses, with manufacturing process claims.
- The patent has broad claims in the use and method categories, protecting core invention while allowing for some variation.
- The Brazilian patent landscape in this class shows active filings, with no current opposition or litigations for this particular patent.
- Expiry is anticipated around 2039, supporting market exclusivity for nearly two decades post-filing.
Key Takeaways
- The patent’s claims protect a specific chemical structure and its approved therapeutic use.
- Exclusivity in Brazil is supported by narrow chemical claims and broad use claims.
- The patent landscape shows active competitors and patent filings in Brazil, with no current litigations.
- R&D should consider potential design-around options and related patents for freedom to operate.
- Strategic licensing or partnerships can optimize commercial leverage before patent expiry.
FAQs
Q1: Does the patent’s scope cover all formulations of the drug?
A: No, it primarily covers the specific chemical entity, its synthesis, and particular uses. Formulations with different excipients may not be protected unless explicitly claimed.
Q2: Can a competitor develop similar drugs in Brazil?
A: They can, if they design around the patent by altering the chemical structure, synthesis process, or therapeutic application not covered in claims.
Q3: When does the patent expire?
A: Assuming standard patent terms and no extensions, expiration is around 2039.
Q4: Are there existing oppositions to this patent?
A: No public records show opposition as of the latest available data.
Q5: How can patent landscape influence R&D strategies?
A: It highlights the protected scope, potential freedom-to-operate issues, and opportunities for licensing or developing alternative compounds.
References
[1] Brazilian Patent Office (INPI). (2023). Patent search database.
[2] World Intellectual Property Organization. (2023). Patent collaboration search.
[3] European Patent Office. (2023). Patent family analysis reports.
[4] Brasil Patent Law (Law No. 9279/1996).
